Language

CAS No. 851199-59-2 | Linaclotide

Name: Linaclotide CAS No. 851199-59-2 MF:C59H79N15O21S6 MW:1526.74 Purity:98% Package: 10mg,25mg,50mg,100mg,250mg Worldwide Delivery

Categories：

Other Life Science Chemicals

Email：sale06@alfachem.cn

Inquiry

Chat Now

Product introduction

Introduction and application of CAS No. 851199-59-2 | Linaclotide

Synonyms:LinaelotideAcetate;

Linaelotide;

CY-14;

Liclotide;

Argpessin;

L-Tyrosine,L-cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-,cyclic(1→6),(2→10),(5→13)-tris(disulfide);

LinaclotideUSP/EP/BP

Specification:

ITEMS	SPECIFICATION
CAS	851199-59-2
MF	C59H79N15O21S6
MW	1526.74
Melting point	231-235°C
Boiling point	2045.0±65.0 °C
Density	1.60
Acidity coefficient	3.05±0.10
Color	White
Solubility	Soluble in DMSO (slightly heated), methanol ((slightly heated)), water (slightly heated)
Form	Solid
Storage condition	Hygroscopic, Refrigerator, under inert atmosphere

Overview:

Linaclotide, also known as linaclotide acetate, trade name Linzess, is a synthetic peptide structure containing 14 amino acids, related to the endogenous guanosine peptide family, and is the only FDA-approved drug for clinical use. GC-C (guanylyl cyclase-C) agonist drugs that act locally in the intestine and can be used to treat adult patients with constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC) .

Physical and chemical properties:

Linaclotide is a white to off-white amorphous powder; slightly soluble in water and sodium chloride aqueous solution (0.9%)

Mechanism:

Linaclotide is a guanylate cyclase-C receptor agonist (GCCA) with both visceral analgesic effects and endocrine activity. Both linaclotide and its active metabolite bind to guanylyl cyclase-C (GC-C) receptors on the luminal surface of the small intestinal epithelium. In animal models, linaclotide reduces visceral pain and increases gastrointestinal transit velocity through activation of GC-C, and in humans, the drug also increases colonic transit velocity. The result of GC-C activation is an increase in the concentration of cGMP (cyclic guanosine monophosphate) inside and outside the cell. Extracellular cGMP can reduce the activity of pain nerve fibers and reduce visceral pain in model animals. Intracellular cGMP can increase the secretion of chloride and bicarbonate in the small intestinal lumen by activating CFTR (cystic fibrosis transmembrane conductance regulator), ultimately leading to increased secretion of small intestinal fluid and increased intestinal transit speed.

Package and transportation :

Package: 10mg,25mg,50mg,100mg,250mg